Agreement supports the development of molecules targeting acute myeloid leukemia, multiple myeloma, human papilloma virus (HPV) associated tumors, and additional human leukocyte antigens (HLAs) tha...
The certification ensures that the CE marked diagnostic products supplied by MBL adhere to standards of quality and safety that ensure the highest level of patients’ health protection
The KBI and Selexis co-location will expand biopharmaceutical development and manufacturing capabilities to serve the global demand for novel therapies.
KBI Biopharma and Selexis, announced today that an expanded, fully-integrated mammalian contract development and manufacturing services facility is now open and operational in Geneva, Switzerland.
JSR Corporation announced today that it has entered into a facility usage agreement with AuB, a company engaged in the study of intestinal microbiota in athletes.
JSR Corporation announced today that it has concluded a facility use agreement with KINS Co., Ltd. (KINS), a company with a database of human microbiome.
Crown Bioscience and MBL announce the formation of a joint venture, to further expand the provision of Crown Bioscience’s preclinical services to Japanese customers.
Selexis SA announced today that Great Place to Work® has designated the Company among the “Best Workplaces Switzerland™” in 2022. This is the fifth straight year Selexis has earned this recognition.
Newly launched business line leverages the combined experience and technical knowledge of leaders in analytical, cell-line, and process development to reduce up-front time and resource costs for bi...
KBI, a JSR Life Sciences company, held a ribbon-cutting at the company’s new state-of-the-art $150 million, 150,000 square-foot commercial manufacturing facility in Research Triangle Park (RTP), No...
2 of 4
Receive JSR Life Sciences news on your RSS reader.